Profile data is unavailable for this security.
About the company
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
- Revenue in USD (TTM)501.00k
- Net income in USD-50.45m
- Incorporated2009
- Employees32.00
- LocationCardiff Oncology Inc11055 Flintkote AveSAN DIEGO 92121-1220United StatesUSA
- Phone+1 (858) 952-7570
- Fax+1 (858) 217-4768
- Websitehttps://cardiffoncology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cognition Therapeutics Inc | 0.00 | -27.99m | 98.87m | 25.00 | -- | 2.71 | -- | -- | -0.4816 | -0.4816 | 0.00 | 0.4138 | 0.00 | -- | -- | 0.00 | -78.86 | -59.00 | -108.44 | -75.05 | -- | -- | -- | -- | -- | -3,450.08 | 0.00 | -- | -- | -- | -31.73 | -- | -51.16 | -- |
| Actuate Therapeutics Inc | 0.00 | -24.12m | 100.64m | 10.00 | -- | 9.20 | -- | -- | -1.19 | -1.19 | 0.00 | 0.4705 | 0.00 | -- | -- | 0.00 | -150.86 | -- | -282.00 | -- | -- | -- | -- | -- | -- | -- | 0.0357 | -- | -- | -- | -10.27 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -106.03m | 100.96m | 30.00 | -- | 1.24 | -- | -- | -2.20 | -2.20 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -59.99 | -28.22 | -85.37 | -29.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 74.96 | -- | 41.75 | -- |
| Turn Therapeutics Inc | -100.00bn | -100.00bn | 103.35m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Goldenwell Biotech Inc | 62.50k | -75.13k | 103.95m | -- | -- | -- | -- | 1,663.20 | -0.0007 | -0.0007 | 0.0006 | -0.001 | 0.3126 | 0.00 | -- | -- | -37.58 | -95.49 | -41.82 | -110.12 | 100.00 | 52.18 | -120.21 | -2,064.27 | 1.16 | -4.11 | 124.14 | -- | -92.39 | -13.55 | -12.05 | -- | -- | -- |
| Korro Bio Inc | 7.37m | -88.42m | 105.19m | 87.00 | -- | 1.06 | -- | 14.27 | -9.42 | -9.42 | 0.7855 | 10.54 | 0.0364 | -- | 1.36 | 70,875.00 | -43.65 | -- | -46.92 | -- | -- | -- | -1,199.53 | -- | -- | -- | 0.00 | -- | -- | -- | -2.97 | -- | -- | -- |
| Agenus Inc | 106.83m | -35.38m | 105.53m | 316.00 | -- | -- | -- | 0.9879 | -2.09 | -2.09 | 3.94 | -8.35 | 0.4523 | -- | 286.79 | 338,066.50 | -16.63 | -58.29 | -- | -140.29 | 98.93 | 97.31 | -36.77 | -125.67 | -- | -1.17 | 6.78 | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
| Citius Oncology Inc | 0.00 | -24.76m | 107.70m | -- | -- | 2.27 | -- | -- | -0.3400 | -0.3400 | 0.00 | 0.5372 | 0.00 | -- | -- | -- | -26.72 | -- | -48.02 | -- | -- | -- | -- | -- | 0.1062 | -129.48 | 0.0781 | -- | -- | -- | -17.08 | -- | -- | -- |
| Cardiff Oncology Inc | 501.00k | -50.45m | 107.78m | 32.00 | -- | 2.20 | -- | 215.12 | -0.7976 | -0.7976 | 0.0079 | 0.7272 | 0.0079 | -- | 1.15 | 15,656.25 | -79.61 | -32.23 | -101.41 | -34.83 | -- | -- | -10,064.27 | -7,588.71 | -- | -- | 0.00 | -- | 39.96 | 22.80 | -9.62 | -- | 3.42 | -- |
| MacroGenics Inc | 127.63m | -75.89m | 108.17m | 341.00 | -- | 1.61 | -- | 0.8476 | -1.21 | -1.21 | 2.02 | 1.06 | 0.4769 | 5.23 | 3.27 | 374,266.90 | -28.36 | -33.40 | -35.18 | -40.60 | 75.41 | -- | -59.46 | -97.17 | 5.02 | -26.97 | 0.5119 | -- | 155.26 | 18.50 | -639.30 | -- | -2.88 | -- |
| Codexis Inc | 52.93m | -63.95m | 108.39m | 188.00 | -- | 2.81 | -- | 2.05 | -0.7514 | -0.7514 | 0.6238 | 0.4269 | 0.389 | 5.42 | 4.03 | 281,553.20 | -47.00 | -21.95 | -58.53 | -26.20 | 79.31 | 76.67 | -120.82 | -49.88 | 4.02 | -- | 0.5076 | -- | -15.39 | -2.82 | 14.38 | -- | 2.91 | -- |
| Immunic Inc | 0.00 | -103.05m | 109.76m | 91.00 | -- | 8.57 | -- | -- | -0.8362 | -0.8362 | 0.00 | 0.1064 | 0.00 | -- | -- | 0.00 | -195.41 | -83.24 | -396.11 | -96.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.37 | -- | 36.85 | -- |
| Coya Therapeutics Inc | 3.99m | -18.43m | 110.44m | 8.00 | -- | 2.89 | -- | 27.69 | -1.11 | -1.11 | 0.2397 | 1.63 | 0.118 | -- | -- | 498,462.50 | -54.54 | -- | -59.84 | -- | -- | -- | -462.26 | -- | -- | -- | 0.00 | -- | -40.79 | -- | -86.29 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 182.33k | -108.09m | 110.61m | 134.00 | -- | -- | -- | 606.66 | -2.63 | -2.63 | 0.0046 | -0.1441 | 0.0021 | -- | 0.1283 | 1,360.67 | -122.52 | -58.57 | -260.08 | -70.33 | -- | -- | -59,283.97 | -4,810.90 | -- | -6.49 | -- | -- | -73.83 | -44.44 | 20.62 | -- | -13.16 | -- |
| Oncolytics Biotech Inc | 0.00 | -25.87m | 113.92m | 29.00 | -- | 1,300.77 | -- | -- | -0.2877 | -0.2877 | 0.00 | 0.0008 | 0.00 | -- | -- | -- | -179.40 | -75.50 | -293.88 | -87.03 | -- | -- | -- | -- | -- | -- | 0.879 | -- | -- | -- | -14.26 | -- | 85.40 | -- |
| Genelux Corp | 0.00 | -31.87m | 116.70m | 24.00 | -- | 5.28 | -- | -- | -0.8803 | -0.8803 | 0.00 | 0.4943 | 0.00 | -- | -- | 0.00 | -97.69 | -125.27 | -116.81 | -- | -- | -- | -- | -830.46 | -- | -- | 0.00 | -- | -95.29 | -- | -5.56 | -- | -26.46 | -- |
Data as of Feb 17 2026. Currency figures normalised to Cardiff Oncology Inc's reporting currency: US Dollar USD
25.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.69m | 5.48% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.25m | 4.82% |
| Laurion Capital Management LPas of 31 Dec 2025 | 2.65m | 3.93% |
| William Blair & Co. LLC (Investment Management)as of 30 Sep 2025 | 2.21m | 3.29% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.52m | 2.26% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 1.21m | 1.79% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.19m | 1.77% |
| F.L. Putnam Investment Management Co.as of 31 Dec 2025 | 595.33k | 0.88% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 519.75k | 0.77% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 447.14k | 0.66% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
